Cannabis Use Disorder, Moderate Clinical Trial
— BEATOfficial title:
Brain Exercise and Addiction Trial: Efficacy of a 12-week Aerobic Exercise Regime for Restoring 'Brain Health' in Cannabis Users
Verified date | October 2023 |
Source | Monash University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Heavy cannabis use is associated with substantive learning and memory impairments and elevated risk of psychopathology. It has been repeatedly demonstrated that the hippocampus, centrally implicated in these processes, is particularly vulnerable to the deleterious effects of prolonged exposure to cannabis. This deterioration of hippocampal structure, function, and biochemistry can be reversed, but this requires two or more years of abstinence from cannabis. However, most heavy cannabis users find it extremely difficult to maintain abstinence over extended periods and current treatments for cannabis use disorders are inadequate. There is a pressing clinical need for an intervention that rapidly accelerates hippocampal recovery, ameliorates the associated cognitive impairments and mental health symptoms, and leads to improved treatment outcomes. One promising candidate is physical exercise. In addition to the well-known physical health benefits, regular exercise also has a potent positive effect on brain health. The current study will investitive the capacity of two different neuroscientifically-informed 12-week exercise programs can restore brain health for heavy long term cannabis users.
Status | Completed |
Enrollment | 65 |
Est. completion date | November 21, 2022 |
Est. primary completion date | June 10, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Aged 20-55 years 2. Voluntary and able to provide informed consent 3. Fluent in English 4. Current moderate - severe cannabis use disorder 5. Major history of cannabis use (i.e. =3 days per week on average for =4 of the past 6 years) 6. Capacity to tolerate physical exercise according to 'Fitness to Exercise' Exclusion Criteria: 1. Have a history of cardiovascular disease, high blood pressure, musculoskeletal injury or other condition that would preclude safe engagement in VO2 max fitness testing and/or regular physical exercise 2. Severe claustrophobia, non-MR compatible metallic implant, or other contraindication to MRI scanning 3. Lifetime history of significant neurological illness, or moderate - severe brain injury, 4. Current major unstable medical illness or chronic pain condition 5. Lifetime history of schizophrenia, schizoaffective disorder, OCD, PTSD, bipolar disorder 6. Current significant depression or anxiety that precludes ability to reliably engage in the exercise program 7. Current moderate - severe substance use disorder for substances other than cannabis (excluding nicotine) 8. Currently pregnant or lactating 9. Shift work employment schedule within the prior 6-months 10. Have engaged in =5 sessions of HITT or resistance training within the past 12-months 11. History of treatment with antipsychotic medications 12. Current participation in psychosocial treatment for substance use disorder 13. Other psychoactive medications or psychosocial treatments will be considered on a case-by-case basis. Where a current psychoactive medication is deemed acceptable, both dose and type must have been stable for a minimum of four weeks prior to baseline assessment, and remain stable throughout the 12-week exercise phase of the study. |
Country | Name | City | State |
---|---|---|---|
Australia | Monash University, BrainPark | Melbourne | Victoria |
Lead Sponsor | Collaborator |
---|---|
Monash University | Turning Point |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in hippocampal integrity | Composite score derived from three hippocampal health indices: volume (structural MRI), connectivity (DTI), neuronal health (MRS NAA) calculated as described in Yucel et al (2016), doi:10.1038/tp.2015.201. | Baseline (0 months), post (3 months) | |
Secondary | Change in cannabis use | Time line follow back | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in cannabis dependence | Severity of Dependence Scale (SDS; range = 0-15 higher scores indicate higher dependence | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in cannabis craving | Penn Craving Scale (PCS; range = 0 - 30 higher scores indicate greater craving) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in depression symptoms | Quick Inventory of Depressive Symptomology (QUIDS; range = 0 - 27 higher scores indicate greater depression symptom severity) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in anxiety symptoms | StateTrait Anxiety Inventory (STAI; range = 20 to 80, higher scores indicate greater anxiety) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in resilience | Connor David Resilience Scale (CDRS; range = 0-100 higher scores indicate higher resilience) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in coping skills | Perceived Stress Scale (10 item; range = 0 - 40 higher scores indicate greater stress) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in sleep quality | Pittsburgh Sleep Quality Index (PSQI; range = 0 to 21 higher scores indicate worse sleep quality) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in mental wellbeing | Warwick Edinburgh Mental Wellbeing Scale (WEMWBS; range = 14-70 higher scores indicate increased mental well being) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in quality of life | Quality of Life and Satisfaction Questionnaire - Short Form (QOL-SF; range = 70 higher scores indicate greater life satisfaction and enjoyment) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in memory | Rey Auditory Verbal Learning Test (RAVLT) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in associative memory | Paired Associates Learning Task (PAL) | Baseline (0 months), post (3 months), follow up (6 months) | |
Secondary | Change in visual memory | Figural Memory Tasks | Baseline (0 months), post (3 months) | |
Secondary | Change in cardiorespiratory fitness | VO2 max | Baseline (0 months), post (3 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04106336 -
Cortical Excitability and Role of rTMS in Cannabis Use Disorder
|
Early Phase 1 | |
Recruiting |
NCT04964739 -
Gender/Sex & CUD Remission
|
N/A | |
Not yet recruiting |
NCT06225232 -
Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study
|
Phase 2 | |
Completed |
NCT04923230 -
Pilot Test of Parent-Focused Cannabis-Related Actions and Practices Intervention for Adolescent Marijuana Abuse
|
N/A | |
Recruiting |
NCT05064319 -
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
|
Phase 2 | |
Active, not recruiting |
NCT04567394 -
Cannabis Use Disorder Treatment Study
|
N/A |